Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Celgene
NCT07053436 · High Risk Newly Diagnosed Multiple Myeloma
NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM)
NCT07030517 · Multiple Myeloma
NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more
NCT06106945 · Multiple Myeloma
Local Institution - 119
Denver, Colorado
Local Institution - 104
Tampa, Florida
Local Institution - 108
Atlanta, Georgia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions